Santhera Pharmaceuticals Holding AG

Santhera Pharmaceuticals Holding AG

Santhera Pharmaceuticals Holding AG (Santhera) is a Swiss company focused on discovery, development and commercialization of small-molecule pharmaceutical products for the treatment of severe neuromuscular diseases. CATENA is Santhera’s first product approved in Canada for symptomatic treatment of Friedreich's ataxia. Santhera has five clinical-stage development programs, three of which investigate its core compound, SNT-MC17/idebenon, in the treatment of Friedreich’s ataxia, Duchenne muscular dystrophy and Leber’s hereditary optic neuropathy. Another clinical program investigates JP-1730/fipamezole in the treatment of dyskinesia in Parkinson’s disease. The fifth program concerns congenital muscular dystrophies. It operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, engaged in research and development of pharmaceuticals, Santhera Pharmaceuticals (Canada), Inc., active in marketing and sales of pharmaceuticals, and Santhera Pharmaceuticals (USA), Inc.

Contact Details

Office Address

Santhera Pharmaceuticals Holding AG
Hammerstrasse 49
Liestal, Switzerland 4410
Phone: +41-61-906-89-50
Fax: +41-61-906-89-51

Executives

Chairman

Michael Lytton

CEO and Director

Klaus Schollmeier

Business Reviews for Santhera Pharmaceuticals Holding AG

Related Companies